Literature DB >> 2248738

Oncogene amplification in squamous cell carcinoma of the head and neck.

W D Merritt1, M C Weissler, B F Turk, T M Gilmer.   

Abstract

Cellular oncogenes appear to be involved in the control of normal cell growth and differentiation. The abnormal activation of these genes in naturally occurring and experimentally induced cancers may have an important role in the expression of the malignant phenotype in cancer cells. Mechanisms for the activation of these genes include chromosomal translocation, point mutation, and DNA amplification. The amplification of specific oncogenes correlates with clinical prognosis in several human malignancies, including breast cancer and neuroblastoma. We examined 21 fresh-frozen human squamous cell carcinomas of the aerodigestive tract for amplification of 10 known cellular oncogenes (c-myc, N-myc, L-myc, N-ras, H-ras, K-ras, erb-B, erb-B2, raf, and int-2), using Southern blotting techniques. Eleven of 21 tumors demonstrated a two-fold to 11-fold amplification of the int-2 oncogene, one member of a family of genes related to basic fibroblast growth factor. Amplification of c-myc, a gene that codes for a DNA-binding protein involved in the regulation of cell growth, was seen in two tumors. None of the other eight genes studied were amplified in any of the tumor specimens.

Entities:  

Mesh:

Year:  1990        PMID: 2248738     DOI: 10.1001/archotol.1990.01870120040005

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  9 in total

Review 1.  The role of oncogenes and tumour-suppressor genes in the aetiology of oral, head and neck squamous cell carcinoma.

Authors:  J K Field
Journal:  J R Soc Med       Date:  1995-01       Impact factor: 5.344

2.  Chromosome 3p loss of heterozygosity and mutation analysis of the FHIT and beta-cat genes in squamous cell carcinoma of the head and neck.

Authors:  M V González; M F Pello; P Ablanedo; C Suárez; V Alvarez; E Coto
Journal:  J Clin Pathol       Date:  1998-07       Impact factor: 3.411

3.  Overexpression of cortactin increases invasion potential in oral squamous cell carcinoma.

Authors:  Shin-ichi Yamada; Souichi Yanamoto; Goro Kawasaki; Akio Mizuno; Takayuki K Nemoto
Journal:  Pathol Oncol Res       Date:  2010-01-13       Impact factor: 3.201

4.  Protein tyrosine kinase activity in laryngeal squamous cell carcinoma.

Authors:  H P Verschuur; G Rijksen; G P Schipper-Kester; P J Slootweg; G J Hordijk; G E Staal
Journal:  Eur Arch Otorhinolaryngol       Date:  1993       Impact factor: 2.503

Review 5.  Chromosomal imbalances in oral squamous cell carcinoma: examination of 31 cell lines and review of the literature.

Authors:  Christa Lese Martin; Shalini C Reshmi; Thomas Ried; William Gottberg; John W Wilson; Jaya K Reddy; Poornima Khanna; Jonas T Johnson; Eugene N Myers; Susanne M Gollin
Journal:  Oral Oncol       Date:  2007-08-02       Impact factor: 5.337

6.  c-myc copy number gains in bladder cancer detected by fluorescence in situ hybridization.

Authors:  G Sauter; P Carroll; H Moch; A Kallioniemi; R Kerschmann; P Narayan; M J Mihatsch; F M Waldman
Journal:  Am J Pathol       Date:  1995-05       Impact factor: 4.307

7.  CT120: A New Potential Target for c-Myc in Head and Neck Cancers.

Authors:  Elif Baltaci; Betül Seyhan; Onur Baykara; Nur Buyru
Journal:  J Cancer       Date:  2017-03-07       Impact factor: 4.207

8.  Expression of ras oncogene p21 protein in normal and neoplastic laryngeal tissues: correlation with histopathological features and epidermal growth factor receptors.

Authors:  G Scambia; L Catozzi; P Benedetti Panici; G Ferrandina; G Almadori; G Paludetti; G Cadoni; M Distefano; A Piffanelli; S Mancuso
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

9.  A sensitive enzyme-linked immunosorbent assay used for quantitation of epidermal growth factor receptor protein in head and neck carcinomas: evaluation, interpretations and limitations.

Authors:  M E Christensen; F Engbaek; M H Therkildsen; P Bretlau; E Nexø
Journal:  Br J Cancer       Date:  1995-12       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.